AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21967845
Drug: ALA (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALA (2 g/d)
Trial: 21309493
Drug: Flurbiprofen 100
RxNorm normalized name: flurbiprofen 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 100 mg orally 1 hour prior to HSG
Trial: 17681958
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa weight-based dosing (0.75 mcg/kg every 2 weeks for 26 weeks)
Trial: 17681958
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa fixed dosing (50 mcg every 2 weeks for 26 weeks)
Trial: 12167135
Drug: Tizanidine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tizanidine (mean dose 18 mg, titrated to maximum 24 mg over 4 weeks)
Trial: 10210050
Drug: Tramadol 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 0.5 mg x kg(‐1)
Trial: 10210050
Drug: Tramadol 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 0.25 mg x kg(‐1)
Trial: 10210050
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 0.05 ml x kg(‐1)
Trial: 8590121
Drug: Continuous cold
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous cold therapy (cold therapy pads placed over a thin dressing, maintained at 42 degrees F for the immediate postoperative period, used for an average of 3 days)
Trial: 8590121
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (identical operative and postoperative procedure without continuous cold therapy)
Trial: 2709943
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1 therapy
Trial: 2709943
Drug: No prostaglandin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prostaglandin E1 therapy (Control)
Trial: 27282117
Drug: Enhanced treatment-as-usual
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced treatment-as-usual
Trial: 31036412
Drug: Glucomannan (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucomannan (3 g/d for 12 weeks)
Trial: 31036412
Drug: Placebo (maltodextrin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (maltodextrin, 3 g/d for 12 weeks)
Trial: 27489077
Drug: Guided Internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided Internet-based cognitive behavioral therapy (ICBT) for 9 weeks
Trial: 27489077
Drug: Guided Internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided Internet-based cognitive behavioral therapy (ICBT)
Trial: 23786339
Drug: High-dose oxytocin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oxytocin (4 mU/min, increasing every 30 minutes to 64 mU/min)
Trial: 23786339
Drug: Standard-dose oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose oxytocin (2 mU/min, increasing every 30 minutes to 32 mU/min)
Trial: 23786339
Drug: Standard-dose oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose oxytocin
Trial: 19914604
Drug: L-DOPA (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-DOPA (300 mg)
Trial: 12727080
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg b.i.d. for 20 days
Trial: 31072359
Drug: Pyriproxyfen (PPF)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyriproxyfen (PPF) dissemination devices (0.2-0.3 g PPF in clay pots)
Trial: 26885511
Drug: Toyra(®) virtual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toyra(®) virtual reality system combined with conventional therapy
Trial: 21095620
Drug: G-CSF (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (10 μg/kg s.c. for 5 days)
Trial: 8804929
Drug: Inhaled lysine-acetylsalicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled lysine-acetylsalicylate (L-ASA) 90 mg.mL-1
Trial: 8804929
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo (glycine, 30 mg.mL-1)
Trial: 622844
Drug: Ajmaline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ajmaline (50 mg)
Trial: 6368960
Drug: Corynebacterium parvum
RxNorm normalized name: Corynebacterium parvum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corynebacterium parvum (CP) subcutaneous on day 14
Trial: 6368960
Drug: Corynebacterium parvum
RxNorm normalized name: Corynebacterium parvum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corynebacterium parvum (CP) intravenous on day 14
Trial: 6368960
Drug: Corynebacterium parvum
RxNorm normalized name: Corynebacterium parvum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corynebacterium parvum (CP) subcutaneous on day 1
Trial: 6368960
Drug: Corynebacterium parvum
RxNorm normalized name: Corynebacterium parvum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corynebacterium parvum (CP) intravenous on day 1
Trial: 6368960
Drug: VAC/FMC chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAC/FMC chemotherapy
Trial: 30698045
Drug: GP2017 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP2017 (40 mg subcutaneous injection)
Trial: 29752620
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Body Image and Self-Care (CBT-BISC)
Trial: 25689042
Drug: Malabsorption blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Malabsorption blood test (MBT) with pancreatic enzyme administration
Trial: 25689042
Drug: Malabsorption blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Malabsorption blood test (MBT) without pancreatic enzyme administration
Trial: 22483680
Drug: Nabiximols (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabiximols (low dose: 1-4 sprays/day)
Trial: 22483680
Drug: Nabiximols (medium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabiximols (medium dose: 6-10 sprays/day)
Trial: 22483680
Drug: Nabiximols (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabiximols (high dose: 11-16 sprays/day)
Trial: 11682411
Drug: 500 mL
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mL mouth-to-mouth ventilation tidal volume
Trial: 11682411
Drug: 1000 mL
RxNorm normalized name: TPN Bag 1000 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mL mouth-to-mouth ventilation tidal volume
Trial: 2566112
Drug: Acebutolol 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol 600 mg
Trial: 2566112
Drug: Carteolol 20
RxNorm normalized name: carteolol 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carteolol 20 mg
Trial: 269633
Drug: No oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No oxytocin infusion (Control)
Trial: 31488492
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg zoledronic acid (ZA)
Trial: 24144899
Drug: efavirenz (EFV)
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: efavirenz (EFV) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs)
Trial: 21594217
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (2 g amoxicillin single preoperative dose)
Trial: 21594217
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (single preoperative 2 g amoxicillin followed by 500 mg three times daily for 5 days)
Trial: 21594217
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C (postoperative amoxicillin with clavulanic acid 625 mg three times daily for 5 days)
Trial: 16459722
Drug: 30 microg
RxNorm normalized name: Levonorgestrel 30 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 microg once weekly (OW) interferon beta-1a
Trial: 9241002
Drug: Moclobemide 900
RxNorm normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide 900 mg daily
Trial: 29105489
Drug: Short-term CHS
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term CHS + vitamin C (12 g/100 l drinking water)
Trial: 20150450
Drug: Intensified dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified dosing of enteric‐coated mycophenolate sodium (EC‐MPS) - 2880 mg/d for days 0-14, 2160 mg/d for days 15-42, followed by 1440 mg/d
Trial: 20150450
Drug: Standard dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosing of enteric‐coated mycophenolate sodium (EC‐MPS) - 1440 mg/d
Trial: 20150450
Drug: Intensified dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified dosing of enteric‐coated mycophenolate sodium (EC‐MPS)
Trial: 20150450
Drug: Standard dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosing of enteric‐coated mycophenolate sodium (EC‐MPS)
Trial: 1683250
Drug: Abanoquil (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abanoquil (0.5 micrograms kg‐1, intravenous bolus)
Trial: 7228474
Drug: Elsinore pills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elsinore pills (ephedrine and caffeine)
Trial: 26510727
Drug: PanAd3-RSV and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PanAd3-RSV and MVA-RSV vaccines (various combinations)
Trial: 26510727
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of IM MVA-RSV
Trial: 22204725
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy plus bevacizumab (7.5 mg/kg), given every 3 weeks for 5 or 6 cycles and continued for 12 additional cycles or until progression of disease.
Trial: 22204725
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (carboplatin and paclitaxel), given every 3 weeks for 6 cycles.
Trial: 22204725
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy plus bevacizumab (7.5 mg/kg).
Trial: 22204725
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (carboplatin and paclitaxel).
Trial: 17202550
Drug: Integrated group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated group therapy
Trial: 21689897
Drug: Group drug
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group drug counseling
Trial: 335791
Drug: L-tryptophan (L-TP)
RxNorm normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-tryptophan (L-TP) 6 g daily with unilateral ECT
Trial: 335791
Drug: L-TP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-TP treatment
Trial: 335791
Drug: L-TP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-TP treatment with ECT
Trial: 26967236
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (systolic blood pressure target of less than 120 mm Hg)
Trial: 26967236
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (systolic blood pressure target of less than 140 mm Hg)
Trial: 21555684
Drug: Anastrozole plus
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anastrozole plus goserelin (3.6 mg subcutaneously every 28 days)
Trial: 16822129
Drug: Grasping and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grasping and using an object (e.g., drinking from a cup)
Trial: 8791035
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg 5-HTP
Trial: 8791035
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg 5-HTP
Trial: 8791035
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg 5-HTP
Trial: 25607709
Drug: Sinecatechins 15%
RxNorm normalized name: SINECATECHINS 15% OINT,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinecatechins 15% ointment BID
Trial: 23121257
Drug: Aspirin 150
RxNorm normalized name: aspirin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 150 mg/day
Trial: 15717109
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with myasthenia gravis (MG)
Trial: 11147733
Drug: Daily-disposable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily-disposable
Trial: 9301443
Drug: GM-CSF, 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF, 300 micrograms/day administered subcutaneously on days 3-6, 10-13, 17-20, and 24-27 during chemotherapy
Trial: 9301443
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered during chemotherapy
Trial: 8421111
Drug: 0.12% chlorhexidine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% chlorhexidine, 100 ppm fluoride mouthrinse, rinsed 2x per day for 1 min with 15 ml for 6 weeks
Trial: 3950051
Drug: Trimoprostil 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimoprostil 0.25 mg
Trial: 3950051
Drug: Trimoprostil 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimoprostil 0.75 mg
Trial: 3089691
Drug: Trimoprostil 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimoprostil 1.5 mg
Trial: 3089691
Drug: Trimoprostil 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimoprostil 3.0 mg
Trial: 3950051
Drug: Trimoprostil (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimoprostil (0.75 mg to 3.0 mg)
Trial: 22422589
Drug: Percutaneous coronary
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous coronary intervention (PCI) using drug-eluting stents (DES) (n=556)
Trial: 18672531
Drug: NVP 400
RxNorm normalized name: NVP
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NVP 400 mg per day
Trial: 18672531
Drug: NVP 600
RxNorm normalized name: NVP
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NVP 600 mg per day
Trial: 16306519
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (1000 mg per day, increased to 3000 mg per day)
Trial: 12475577
Drug: Short-term low-dose
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term low-dose heparin plus bedrest
Trial: 1503287
Drug: Cefamandole intravenously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefamandole intravenously every four hours, three times, starting from induction of anaesthesia (1.5 g for <60 kg, 2.5 g for 60-80 kg, 3 g for >80 kg)
Trial: 1503287
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered at the same times
Trial: 6434168
Drug: 2% sodium
RxNorm normalized name: Dextrose 5% and 0.2% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% sodium cromoglycate ophthalmic solution
Trial: 6434168
Drug: 4% sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% sodium cromoglycate ophthalmic solution
Trial: 27792720
Drug: simvastatin plus
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: simvastatin plus inulin (20 mg simvastatin, 7 g inulin)
Trial: 27792720
Drug: simvastatin plus
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: simvastatin plus ezetimibe (20 mg simvastatin, 10 mg ezetimibe)
Trial: 23046608
Drug: Trauma-Focused Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trauma-Focused Cognitive Behavioral Therapy (TF-CBT) (10-12 weeks)
Trial: 17586424
Drug: n-3 PUFA
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFA (2.4 g daily for 8 weeks)
Trial: 17586424
Drug: Control (olive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (olive oil, 2.4 g daily for 8 weeks)
Trial: 10023787
Drug: Dexamethasone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.5 mg/kg/d for 1 week, then tapered over 3 weeks)
Trial: 2216227
Drug: Topical bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical bupivacaine hydrochloride on both fallopian tubes
Trial: 2216227
Drug: Topical bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical bupivacaine hydrochloride on the right fallopian tube only
Trial: 2216227
Drug: Topical bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical bupivacaine hydrochloride on the left fallopian tube only
Trial: 31194960
Drug: Biting activity
RxNorm normalized name: PAD,BITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biting activity of An. gambiae s.l. outdoors
Trial: 31194960
Drug: Biting activity
RxNorm normalized name: PAD,BITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biting activity of An. funestus s.l. outdoors
Trial: 31194960
Drug: Biting activity
RxNorm normalized name: PAD,BITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biting activity of An. funestus s.l. indoors
Trial: 31194960
Drug: Biting activity
RxNorm normalized name: PAD,BITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biting activity of An. gambiae s.l. during wet season
Trial: 31194960
Drug: Biting location
RxNorm normalized name: Potassium cation
DrugBank: Potassium cation (DB01345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biting location preference of An. gambiae s.l.
Trial: 31194960
Drug: Biting location
RxNorm normalized name: Potassium cation
DrugBank: Potassium cation (DB01345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biting location preference of An. funestus s.l. during wet season
Trial: 31194960
Drug: Biting location
RxNorm normalized name: Potassium cation
DrugBank: Potassium cation (DB01345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biting location preference of An. funestus s.l. during dry season
Trial: 28785809
Drug: Mud-bath therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mud-bath therapy (MBT) group: daily treated with a combination of local mud-packs at 42 °C and baths in mineral water at 37 °C for 15 min, for 12 applications over a period of 2 weeks, in addition to standard therapy.
Trial: 28785809
Drug: Control group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group: continued their conventional treatment alone.
Trial: 25874654
Drug: Drug prescriptions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug prescriptions
Trial: 24132057
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light + melatonin capsule
Trial: 24132057
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light + placebo capsule
Trial: 24132057
Drug: Dim light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dim light (placebo) + melatonin capsule
Trial: 24132057
Drug: Dim light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dim light (placebo) + placebo capsule
Trial: 24132057
Drug: Combined bright
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined bright light + melatonin treatment
Trial: 19175712
Drug: Lafutidine 10
RxNorm normalized name: lafutidine
DrugBank: Lafutidine (DB12770)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lafutidine 10 mg twice daily for 12 weeks plus gargling with azulene sulfonate sodium (ASS)
Trial: 16394041
Drug: Water-based lubricant
RxNorm normalized name: Trojan H2O Closer Water-Based Lubricants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water-based lubricant (0.5 mL contaminated specimen)
Trial: 1759375
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment with psychotherapy
Trial: 1759375
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment without psychotherapy
Trial: 6176753
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (Velban, Bleomycin, Cis-Platinum, Ifosfamid)
Trial: 17413907
Drug: Remifentanil 0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 0 ng/ml
Trial: 17413907
Drug: Remifentanil 2
RxNorm normalized name: remifentanil 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 2 ng/ml
Trial: 22289530
Drug: Remifentanil 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 4 ng/ml
Trial: 10459691
Drug: Methylcobalamin (Met-12)
RxNorm normalized name: Met
DrugBank: Mecobalamin (DB03614)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylcobalamin (Met-12) - large dosage
Trial: 10459691
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group - small dosage